Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation - PubMed (original) (raw)
. 1994 May 26;369(6478):333-6.
doi: 10.1038/369333a0.
Affiliations
- PMID: 7514277
- DOI: 10.1038/369333a0
Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation
B H Nelson et al. Nature. 1994.
Abstract
The interleukin-2 receptor (IL-2R) consists of three distinct chains (alpha, beta, gamma) which bind IL-2 and generate a proliferative signal in T cells. To define the mechanism of receptor activation, chimaeric receptors were constructed from the intracellular region of either IL-2R beta or IL-2R gamma and the extracellular region of c-kit, a receptor tyrosine kinase that homodimerizes on binding stem cell factor (SCF). We report here that binding of SCF to the beta-chain chimaera induced proliferation of the pro-B-cell line BA/F3, but not T cells. But in T cells expressing both the beta- and gamma-chain chimaeras, SCF induced proliferation and tyrosine phosphorylation characteristic of the native IL-2R signal. Chimaeric IL-2 receptor beta and gamma chains constructed with the heterodimeric extracellular regions of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) also provided the IL-2R signal. Thus, heterodimerization of the cytoplasmic domains of IL-2R beta and -gamma appears necessary and sufficient for signalling in T cells.
Similar articles
- Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling.
Nakamura Y, Russell SM, Mess SA, Friedmann M, Erdos M, Francois C, Jacques Y, Adelstein S, Leonard WJ. Nakamura Y, et al. Nature. 1994 May 26;369(6478):330-3. doi: 10.1038/369330a0. Nature. 1994. PMID: 8183373 - Signal transduction mediated by the reconstituted IL-2 receptor. Evidence for a cell type-specific function of IL-2 receptor beta-chain.
Minami Y, Oishi I, Liu ZJ, Nakagawa S, Miyazaki T, Taniguchi T. Minami Y, et al. J Immunol. 1994 Jun 15;152(12):5680-90. J Immunol. 1994. PMID: 8207200 - Interaction of the erythropoietin and stem-cell-factor receptors.
Wu H, Klingmüller U, Besmer P, Lodish HF. Wu H, et al. Nature. 1995 Sep 21;377(6546):242-6. doi: 10.1038/377242a0. Nature. 1995. PMID: 7545788 - The human interleukin-2 receptor: insights into subunit structure and growth signal transduction.
Fung MR, Greene WC. Fung MR, et al. Semin Immunol. 1990 Mar;2(2):119-28. Semin Immunol. 1990. PMID: 2129904 Review. - The interleukin-2 receptor complex and signal transduction: role of the beta-chain.
Kono T, Minami Y, Taniguchi T. Kono T, et al. Semin Immunol. 1993 Oct;5(5):299-307. doi: 10.1006/smim.1993.1036. Semin Immunol. 1993. PMID: 8260646 Review.
Cited by
- Mechanism of Fuzheng Qudu prescription in the treatment of lung cancer based on network pharmacology and experimental validation.
Su B, Mao Q, Li D, Wu Y, Wang B, Wang X. Su B, et al. Heliyon. 2024 Sep 6;10(18):e37546. doi: 10.1016/j.heliyon.2024.e37546. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309919 Free PMC article. - Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends.
Im SJ, Lee K, Ha SJ. Im SJ, et al. Exp Mol Med. 2024 Sep;56(9):1900-1908. doi: 10.1038/s12276-024-01301-3. Epub 2024 Sep 2. Exp Mol Med. 2024. PMID: 39218982 Free PMC article. Review. - Tyrosine phosphorylation of both STAT5A and STAT5B is necessary for maximal IL-2 signaling and T cell proliferation.
Lin JX, Ge M, Liu CY, Holewinski R, Andresson T, Yu ZX, Gebregiorgis T, Spolski R, Li P, Leonard WJ. Lin JX, et al. Nat Commun. 2024 Aug 27;15(1):7372. doi: 10.1038/s41467-024-50925-6. Nat Commun. 2024. PMID: 39191751 Free PMC article. - Strategies to therapeutically modulate cytokine action.
Leonard WJ, Lin JX. Leonard WJ, et al. Nat Rev Drug Discov. 2023 Oct;22(10):827-854. doi: 10.1038/s41573-023-00746-x. Epub 2023 Aug 4. Nat Rev Drug Discov. 2023. PMID: 37542128 Review. - Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors.
Righi M, Gannon I, Robson M, Srivastava S, Kokalaki E, Grothier T, Nannini F, Allen C, Bai YV, Sillibourne J, Cordoba S, Thomas S, Pule M. Righi M, et al. Cancer Immunol Res. 2023 Sep 1;11(9):1203-1221. doi: 10.1158/2326-6066.CIR-22-0640. Cancer Immunol Res. 2023. PMID: 37352396 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous